
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): 12/23/2010

Dynavax Technologies Corporation

(Exact name of registrant as specified in its charter)

Commission File Number: 001-34207

Delaware
(State or other jurisdiction of
incorporation)

33-0728374
(IRS Employer
Identification No.)

2929 Seventh Street, Suite 100
Berkeley, CA 94710-2753
(Address of principal executive offices, including zip code)

(510) 848-5100
(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 8.01. Other Events

On December 23, 2010, Dynavax Technologies Corporation (Dynavax) issued a press release titled "Dynavax Reports Phase 1b Safety and Immunogenicity Results for Hepatitis B Therapy Candidate." A copy of the press release is attached as Exhibit 99.1 to this current report and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits

(d) Exhibit

Exhibit No.	Description
-------------	-------------

99.1	Press Release, dated December 23, 2010, titled "Dynavax Reports Phase 1b Safety and Immunogenicity Results For Hepatitis B Therapy Candidate."
------	--

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dynavax Technologies Corporation

Date: December 23, 2010

By: /s/ Michael S. Ostrach

Michael S. Ostrach
Vice President

EXHIBIT INDEX

Exhibit No.	Description
EX-99.1	Press Release, dated December 23, 2010, titled "Dynavax Reports Phase 1b Safety and Immunogenicity Results For Hepatitis B Therapy Candidate."

DYNAVAX

DYNAVAX TECHNOLOGIES

2929 Seventh Street, Suite 100

Berkeley, CA 94710

Contact:

Michael Ostrach
Vice President and Chief Business
Officer
510-665-7257
mostrach@dynavax.com

Dynavax Reports Phase 1B Safety and Immunogenicity Results for HEPATITIS B THERAPY CANDIDATE

BERKELEY, CA - December 23, 2010 - Dynavax Technologies Corporation (Nasdaq: DVAX) today reported safety and immunogenicity data from its Phase 1b clinical trial of DV-601, its proprietary hepatitis B therapeutic vaccine. The dose escalation study assessed safety and the immunologic and virologic responses in 14 subjects with chronic hepatitis B infection. The Phase 1b data showed:

- All doses were generally safe and well tolerated; and
- Individual immunologic and virologic responses were observed across cohorts at all dose levels.

No conclusions regarding the potential clinical impact of the therapy could be reached in this small study. Dynavax's treatment approach combines both the surface and core hepatitis B virus (HBV) antigens with ISCOMATRIX[®] adjuvant originally entered into development by Rhein Biotech prior to its acquisition by Dynavax in 2006. The candidate vaccine, DV-601, is designed to induce an immune response against HBV-infected cells and if proven to be safe and effective, may offer an alternative therapeutic option for patients chronically infected with HBV.

About Dynavax

Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious diseases. The Company's lead product candidate is HEPLISAV[™], a Phase 3 investigational adult hepatitis B vaccine designed to enhance protection more rapidly and with fewer doses than current licensed vaccines. For more information visit, www.dynavax.com.

ISCOMATRIX[®] is a registered trademark of CSL Behring

###